EUVIMEDEUVIMED entdecken
Crossref

Pilot Study of Nectin-4–Targeted PET Imaging Agent 68 Ga-FZ-NR-1 in Triple-Negative Breast Cancer from Bench to First-in-Human

Li Sun, Yuyun Sun, Ke Zuo, Lei Fan, Xiao Wang, Jianping Zhang, Silong Hu, Xiaosheng Liu, Jindian Li, Ye Li, Zhiming Shao, Xiaoping Xu und 2 weitere

Journal of Nuclear Medicine · 2025-03 · 66 (3) · 473-479

DOI: 10.2967/jnumed.124.269024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 13.02.2025. Verfasst von Li Sun und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Cell Adhesion Molecules, Gallium Radioisotopes, Positron Emission Tomography Computed Tomography. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nectin cell adhesion molecule 4 (Nectin-4) is an emerging biomarker for cancer diagnosis and therapy. We developed a Nectin-4-targeted 68Ga-DOTA-Sar10-Nectin-4 (68Ga-FZ-NR-1) PET/CT radiotracer for detecting Nectin-4 expression in a tumor model and in triple-negative breast cancer (TNBC) patients.

Methods

A series of Nectin-4-targeted radiotracers-68Ga-FZ-NR-1, 68Ga-DOTA-polyethylene glycol 5-Nectin-4 (68Ga-FZ-NR-2), and 68Ga-DOTA-polyethylene glycol 10-Nectin-4 (68Ga-FZ-NR-3)-were synthesized, and their targeting ability and specificity were evaluated in vitro and in vivo. In vitro experiments were performed in the MDA-MB-468 (Nectin-4-positive) and MDA-MB-231 (Nectin-4-negative) cell lines. PET/CT imaging in tumor models was performed to assess the Nectin-4-targeting ability of the radiotracers. After preclinical experiments and screening, the 68Ga-FZ-NR-1 radiotracer was selected for safety and efficacy evaluation in a first-in-human trial in TNBC patients. Positive lesions were biopsied and analyzed by immunohistochemistry to determine Nectin-4 expression levels.

Results

The 3 68Ga-labeled radiotracers exhibited high radiochemical purity, stability, and strong affinity for Nectin-4. In vitro cell uptake studies showed that the radiotracers effectively targeted Nectin-4 in MDA-MB-468 cells, and 68Ga-FZ-NR-1 showed the highest targeting efficacy. In the MDA-MB-468 tumor model, PET/CT imaging showed that 68Ga-FZ-NR-1 was taken up at higher rates than 68Ga-FZ-NR-2 and 68Ga-FZ-NR-3, and it exhibited favorable pharmacokinetics and safety profiles. 68Ga-FZ-NR-1 was thus selected for subsequent clinical trials. 68Ga-FZ-NR-1 PET/CT effectively identified tumors in 9 patients with TNBC, which was confirmed by 18F-FDG PET/CT. Biopsy samples of the tumor lesions revealed that the positive lesions identified by 68Ga-FZ-NR-1 PET/CT corresponded to areas of high Nectin-4 expression.

Conclusion

A series of Nectin-4-targeted radiotracers (68Ga-FZ-NR-1, 68Ga-FZ-NR-2, and 68Ga-FZ-NR-3) was developed and evaluated. Preclinical studies demonstrated that 68Ga-FZ-NR-1 can identify tumors with high Nectin-4 expression. In a preliminary clinical study, 68Ga-FZ-NR-1 was used to effectively identify and visualize Nectin-4-expressing tumor lesions in patients with TNBC, which was confirmed by immunohistochemistry. This radiotracer provides a noninvasive approach to the assessment of Nectin-4 and a potential basis for the development of Nectin-4-targeted treatments for TNBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsCell Adhesion MoleculesGallium RadioisotopesPositron Emission Tomography Computed TomographyHumansFemaleAnimalsCell Line, TumorPilot ProjectsMiceMiddle AgedRadiopharmaceuticalsTissue DistributionNectins

Stichwörter der Autor:innen

68GaNectin-4PET/CT imagingTNBCradiotracertriple-negative breast cancer

Substanzen

Cell Adhesion MoleculesGallium RadioisotopesNECTIN4 protein, humanGallium-68RadiopharmaceuticalsNectins

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Ningbo Key Laboratory of Biomedical Imaging Probe Materials and Technology, CAS Key Laboratory of Magnetic Materials and Devices, and Laboratory of Advanced Theranostic Materials and Technology, Ningbo Institute of Mate…
  • Zhejiang International Cooperation Base of Biomedical Materials Technology and Application, Zhejiang Engineering Research Center for Biomedical Materials, Ningbo Cixi Institute of Biomedical Engineering, Cixi, China.
  • Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
  • Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, China.
  • Center for Biomedical Imaging, Fudan University, Shanghai, China; and.

Zitieren

APA

Sun, L., Sun, Y., Zuo, K., Fan, L., Wang, X., Zhang, J., Hu, S., Liu, X., Li, J., Li, Y., Shao, Z., Xu, X., Wu, A., & Song, S. (2025). Pilot Study of Nectin-4–Targeted PET Imaging Agent 68 Ga-FZ-NR-1 in Triple-Negative Breast Cancer from Bench to First-in-Human. Journal of Nuclear Medicine, 66(3), 473-479. https://doi.org/10.2967/jnumed.124.269024

Vancouver

Sun L, Sun Y, Zuo K, Fan L, Wang X, Zhang J, et al. Pilot Study of Nectin-4–Targeted PET Imaging Agent 68 Ga-FZ-NR-1 in Triple-Negative Breast Cancer from Bench to First-in-Human. Journal of Nuclear Medicine. 2025;66(3):473-479. doi:10.2967/jnumed.124.269024

BibTeX
@article{Sun2025,
  author = {Sun, Li and Sun, Yuyun and Zuo, Ke and Fan, Lei and Wang, Xiao and Zhang, Jianping and Hu, Silong and Liu, Xiaosheng and Li, Jindian and Li, Ye and Shao, Zhiming and Xu, Xiaoping and Wu, Aiguo and Song, Shaoli},
  title = {Pilot Study of Nectin-4–Targeted PET Imaging Agent 68 Ga-FZ-NR-1 in Triple-Negative Breast Cancer from Bench to First-in-Human},
  journal = {Journal of Nuclear Medicine},
  year = {2025},
  volume = {66},
  number = {3},
  pages = {473--479},
  doi = {10.2967/jnumed.124.269024}
}
Kostenlos starten →